STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNDM
  4. [8-K] TANDEM DIABETES CARE INC Reports Material Event

Tandem Diabetes Care (NASDAQ: TNDM) lifts Q2 sales to $254.6M, trims loss

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tandem Diabetes Care, Inc. reported second quarter 2026 results with worldwide sales of $254.6 million, a 6% increase from $240.7 million, including U.S. sales of $179.3 million and international sales of $75.3 million. Pump shipments exceeded 33,000 units worldwide, with about 22,000 in the U.S. and 11,000 internationally.

Gross profit was $144.8 million and gross margin improved to 57%, up 460 basis points from 52% a year earlier. GAAP operating loss narrowed to $13.8 million, or negative 5% of sales, from $51.8 million, and GAAP net loss was $21.2 million, or $0.31 per share, compared with $52.4 million, or $0.78 per share. Adjusted EBITDA turned positive at $6.4 million, or 3% of sales.

For full-year 2026, Tandem reaffirmed sales guidance of approximately $1.065 billion to $1.085 billion, with U.S. sales of $730 million to $745 million and international sales of $335 million to $340 million. It expects gross margin of about 56% to 57% and adjusted EBITDA margin of about 5% to 6%, and now anticipates approximately $85 million of non-cash charges. Strategically, the company submitted a 510(k) for Tandem Mobi tubeless capability, gained new FDA clearances and CE Marks for Control-IQ+ in additional indications, expanded sensor compatibility with Dexcom G7 and Abbott FreeStyle Libre 3 Plus, and began the international commercial rollout of Tandem Mobi.

Positive

  • None.

Negative

  • None.

Filing Explained

At June 30, reported liquidity stood alongside $602,577 thousand of convertible senior notes; second-quarter operating cash use was $34,623 thousand.

The August 6 Form 8-K furnished, rather than filed, the company’s second-quarter results for the quarter ended June 30, 2026; its accompanying balance sheet reports $455,996 thousand in cash, cash equivalents and short-term investments and $602,577 thousand in long-term convertible senior notes.

Form 8-K reports specified material events within four business days; here, Item 2.02 furnished the results through Exhibit 99.1, which the filing says is not treated as filed under Section 18.

The quarter’s cash-flow table reports GAAP cash used in operating activities of $34,623 thousand, capital expenditures of $4,050 thousand, and non-GAAP free cash flow of $38,673 thousand used. The filing defines free cash flow as cash provided by operating activities less capital expenditures.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Worldwide Sales Q2 2026 $254.6 million Quarter ended June 30, 2026 worldwide sales, a 6% increase from $240.7 million in Q2 2025
Gross Margin Q2 2026 57% Quarter ended June 30, 2026 gross margin versus 52% in Q2 2025, up 460 basis points
GAAP Net Loss Q2 2026 $21.2 million Quarter ended June 30, 2026 GAAP net loss compared to $52.4 million in Q2 2025
Adjusted EBITDA Q2 2026 $6.4 million (3% of sales) Adjusted EBITDA for Q2 2026 versus negative $1.8 million (negative 1% of sales) in Q2 2025
2026 Sales Guidance $1.065 billion to $1.085 billion Estimated full-year 2026 sales range reaffirmed by the company
Cash and Short-Term Investments 455,996 (in thousands) Cash, cash equivalents and short-term investments as of June 30, 2026 on the balance sheet
Convertible Senior Notes Long-Term 602,577 (in thousands) Long-term convertible senior notes balance as of June 30, 2026
Non-cash Charges 2026 Outlook $85 million Estimated 2026 non-cash charges in cost of goods sold and operating expenses
Adjusted EBITDA financial
"Adjusted EBITDA(1) was $6.4 million, or 3% of sales, compared to negative"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
constant currency sales growth financial
"constant currency sales growth, non-GAAP operating loss, and non-GAAP net loss are non-GAAP"
510(k) regulatory
"Submitted 510(k) with the U.S. Food and Drug Administration (FDA) for Tandem Mobi"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
CE Mark regulatory
"Received FDA clearance and CE Mark for the use of Control-IQ+ automated insulin"
A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.
convertible senior notes financial
"Convertible senior notes, net - long-term | 602,577 | | | 310,036"
Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.
non-GAAP free cash flow financial
"Non-GAAP free cash flow (3) | $ | (38,673) | | $ | (15,702)"
Non-GAAP free cash flow is a company’s reported cash generated from operations after paying for routine investments in property and equipment, adjusted by management to exclude or include certain items that aren’t part of standard accounting rules. Investors watch it as a practical measure of the cash a business has available for dividends, stock buybacks, debt repayment or reinvestment — like a household’s usable savings after adjusting for one-time or unusual expenses — but calculations vary between firms, so comparisons require caution.
Worldwide sales Q2 2026 $254.6 million Increased 6% from $240.7 million in Q2 2025
U.S. sales Q2 2026 $179.3 million Increased 5% from $170.2 million in Q2 2025
International sales Q2 2026 $75.3 million Increased 7% from $70.5 million in Q2 2025
Gross margin Q2 2026 57% Up from 52% in Q2 2025, an improvement of 460 basis points
GAAP net loss Q2 2026 $21.2 million Narrowed from $52.4 million GAAP net loss in Q2 2025
Adjusted EBITDA Q2 2026 $6.4 million (3% of sales) Improved from negative $1.8 million (negative 1% of sales) in Q2 2025
Guidance

For 2026, the company estimates sales of approximately $1.065 billion to $1.085 billion, U.S. sales of $730 million to $745 million, international sales of $335 million to $340 million, gross margin of about 56% to 57%, adjusted EBITDA margin of about 5% to 6%, and non-cash charges of approximately $85 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

How did Tandem Diabetes Care (TNDM) perform financially in Q2 2026?
Tandem reported Q2 2026 worldwide sales of $254.6 million, a 6% increase from $240.7 million in Q2 2025. U.S. sales were $179.3 million and international sales were $75.3 million, with total pump shipments above 33,000 units worldwide.

What were Tandem Diabetes Care (TNDM)’s Q2 2026 profitability and margins?
In Q2 2026 Tandem posted a GAAP net loss of $21.2 million, versus $52.4 million a year earlier. Gross margin improved to 57% from 52%, GAAP operating loss narrowed to $13.8 million (negative 5% of sales), and Adjusted EBITDA was $6.4 million, or 3% of sales.

What 2026 revenue and margin guidance did Tandem Diabetes Care (TNDM) provide?
For 2026, Tandem reaffirmed sales guidance of approximately $1.065 billion to $1.085 billion. U.S. sales are estimated at $730–$745 million, international at $335–$340 million, with expected gross margin of 56%–57% and adjusted EBITDA margin of about 5%–6% of sales.

What non-cash expense outlook did Tandem Diabetes Care (TNDM) disclose for 2026?
Tandem now expects approximately $85 million of non-cash charges in 2026, reduced from $100 million. This includes about $65 million of non-cash stock-based compensation expense, down from $80 million, and approximately $20 million of depreciation and amortization expense.

What balance sheet figures did Tandem Diabetes Care (TNDM) report as of June 30, 2026?
As of June 30, 2026, Tandem reported cash, cash equivalents and short-term investments of 455,996 (in thousands) and total assets of 1,154,202 (in thousands). Long-term convertible senior notes totaled 602,577 (in thousands), and total stockholders’ equity was 130,388 (in thousands).

What strategic and regulatory milestones did Tandem Diabetes Care (TNDM) achieve in Q2 2026?
In Q2 2026 Tandem submitted a 510(k) for Tandem Mobi tubeless capability, received FDA clearance and CE Mark for Control-IQ+ in additional diabetes indications, added Dexcom G7 and Abbott FreeStyle Libre 3 Plus sensor compatibility, and began the international commercial rollout of Tandem Mobi.

Which non-GAAP metrics did Tandem Diabetes Care (TNDM) highlight in its Q2 2026 update?
Tandem emphasized Adjusted EBITDA, non-GAAP operating loss, non-GAAP net loss, constant currency sales growth, and free cash flow. Adjusted EBITDA was $6.4 million (3% of sales), and non-GAAP operating loss matched GAAP operating loss at $13.8 million for Q2 2026.
0001438133FALSE00014381332026-08-062026-08-06


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
 Identification No.)
12400 High Bluff Drive92130
San Diego California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________




Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Tandem Diabetes Care, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.
(d)     Exhibits.

 Number
Description
99.1
Press release of Tandem Diabetes Care, Inc. dated August 6, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN
Shannon M. Hansen
Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: August 6, 2026
3
Exhibit 99.1

tandemhorizontallogonewrgba.jpg             Media Contact:
858-366-6900
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com


FOR IMMEDIATE RELEASE

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

San Diego, August 6, 2026 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights
•Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.)
•Gross margin of 57%, up 460 basis points compared to second quarter 2025
•Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in the U.S.
•Operating margin improved 800 basis points compared to second quarter 2025
•Scaled pay-as-you-go reimbursement model resulting in 10% of U.S. sales through the pharmacy channel
Second Quarter 2026 Strategic Highlights
•Submitted 510(k) with the U.S. Food and Drug Administration (FDA) for Tandem Mobi tubeless capability
•Expanded global portfolio of diabetes technology solutions
◦Received FDA clearance and CE Mark for the use of Control-IQ+ automated insulin delivery technology by people with type 1 diabetes during pregnancy, and received CE Mark for use by adults with type 2 diabetes
◦Introduced compatibility with the Dexcom G7 15-day sensor for both t:slim X2 and Tandem Mobi in the U.S.
◦Launched t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor in four European markets
◦Began the international commercial rollout for Tandem Mobi

“Our second quarter results reflect meaningful progress across the priorities we set for 2026,” said John Sheridan, president and chief executive officer. “We are seeing tangible evidence that our strategy is gaining traction and the momentum we are building reinforces our confidence in Tandem’s ability to drive broader customer impact, strengthen our financial performance and create long-term value.”

1
Exhibit 99.1
Second Quarter 2026 Financial Results Compared to Second Quarter 2025
•Sales: Worldwide sales increased 6% to $254.6 million, compared to $240.7 million. Sales increased 5% in constant currency(1).

Sales in the U.S. increased 5% to $179.3 million, compared to $170.2 million.

International sales increased 7% to $75.3 million, compared to $70.5 million. International sales increased 6% in constant currency(1).

Shipments in the U.S. were more than 22,000 pumps, compared to approximately 21,000 pumps.

International shipments were approximately 11,000 pumps, compared to approximately 9,000 pumps.

•Gross profit: Gross profit was $144.8 million, compared to $125.9 million. Gross margin was 57%, compared to 52%.

•Operating loss: GAAP and non-GAAP operating loss(1) was $13.8 million, or negative 5% of sales, compared to GAAP operating loss of $51.8 million, or negative 22% of sales and non-GAAP operating loss(1) of $31.9 million, or negative 13% of sales, in the second quarter 2025. The second quarter 2025 included a $20.0 million charge for litigation settlement expense.

•Net income (loss): GAAP and non-GAAP net loss(1) was $21.2 million, compared to GAAP net loss of $52.4 million and non-GAAP net loss(1) of $32.4 million in the second quarter 2025.

Adjusted EBITDA(1) was $6.4 million, or 3% of sales, compared to negative $1.8 million, or negative 1% of sales.

See tables for additional financial information.

2026 Financial Guidance

For the year ending December 31, 2026, the Company is reaffirming the following financial guidance:
•Sales are estimated to be approximately $1.065 billion to $1.085 billion
•U.S. sales of approximately $730 million to $745 million
•International sales of approximately $335 million to $340 million
•Gross margin is estimated to be approximately 56% to 57% of sales
•Adjusted EBITDA margin(2) is estimated to be approximately 5% to 6% of sales
For the year ending December 31, 2026, the Company is updating its non-cash financial guidance as follows:
•Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million, a reduction from $100 million. This includes:
•Approximately $65 million non-cash, stock-based compensation expense, a reduction from $80 million
•Approximately $20 million depreciation and amortization expense
For a comprehensive overview of the Company's guidance assumptions for 2026, including pricing and transition assumptions for the adoption of pay-as-you go reimbursement in the U.S. and the initiation of international direct operations, please see the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at https://investor.tandemdiabetes.com.

(1)Adjusted EBITDA, constant currency sales growth, non-GAAP operating loss, and non-GAAP net loss are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for additional information on these non-GAAP financial measures. A reconciliation of constant currency to GAAP sales can be found in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release. A reconciliation of non-GAAP operating loss to GAAP operating loss and adjusted EBITDA and non-GAAP net loss to GAAP net loss can be found in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

(2)Adjusted EBITDA margin is a non-GAAP financial measure. The Company has not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the
2
Exhibit 99.1
uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot reasonably be predicted with the level of precision required, the Company is unable to provide outlook for the comparable GAAP measure (net income (loss) as a percentage of sales). Forward-looking estimates of adjusted EBITDA margin are made in a manner consistent with relevant calculations and assumptions noted herein.

Non-GAAP Financial Measures

Certain financial measures presented in this press release are not calculated or presented in accordance with generally accepted accounting principles (GAAP). The Company has provided these non-GAAP financial measures to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company’s management believes these non-GAAP financial measures are important operating performance indicators because they either exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results, or aid in presenting information on a consistent and comparable basis. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, financial measures calculated and presented in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, the Company expects they will be calculated using a consistent method from period to period and, if not, an explanation will be provided.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is a non-GAAP financial measure that is calculated by adding back to GAAP net loss the following items: income tax expense (benefit); interest income, interest expense and other, net; depreciation and amortization; litigation and settlement expense; stock-based compensation expense; and non-recurring facility impairment and restructuring costs. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by GAAP sales. A reconciliation of adjusted EBITDA to GAAP net loss has been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

Constant Currency Sales Growth

Constant currency sales growth is a non-GAAP financial measure that represents the change in sales between current and prior year periods using the exchange rate in effect during the applicable prior year period. A reconciliation of constant currency to GAAP sales has been provided in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release.

Non-GAAP Operating Loss and Non-GAAP Net Loss

Non-GAAP operating loss and non-GAAP net loss are non-GAAP financial measures that are calculated by adding back litigation and settlement expense and non-recurring facility impairment and restructuring costs to GAAP operating loss and GAAP net loss, respectively. Reconciliations of non-GAAP operating loss and non-GAAP net loss to the comparable GAAP financial measures have been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6a4f904373b71317b8eab87d1b) and you will be provided with dial-in details, including a personal pin.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is headquartered in San Diego, California. For more information, visit tandemdiabetes.com.

3
Exhibit 99.1
Tandem Diabetes Care, the Tandem logo, Control-IQ, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the U.S. and/or other countries.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s products; products marketed and sold or under development by competitors; foreign currency exchange rates; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process internationally for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors except as required by law.

# # #
4
Exhibit 99.1
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Table A
(in thousands)
(unaudited)
June 30,December 31,
20262025
Assets
Current assets:
Cash, cash equivalents and short-term investments$455,996 $292,666 
Accounts receivable, net162,065 165,491 
Inventories135,106 128,769 
Other current assets51,472 31,217 
Total current assets804,639 618,143 
Property and equipment, net84,501 83,580 
Operating lease right-of-use assets100,185 96,172 
Equity method investment
132,271 60,351 
Other long-term assets32,606 22,866 
Total assets$1,154,202 $881,112 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable, accrued expenses and employee-related liabilities$142,930 $138,488 
Operating lease liabilities20,265 19,472 
Deferred revenue8,430 9,527 
Other current liabilities81,380 75,237 
Total current liabilities253,005 242,724 
Convertible senior notes, net - long-term602,577 310,036 
Operating lease liabilities - long-term116,411 114,967 
Deferred revenue - long-term7,776 8,474 
Other long-term liabilities44,045 49,741 
Total liabilities1,023,814 725,942 
Total stockholders’ equity130,388 155,170 
Total liabilities and stockholders’ equity$1,154,202 $881,112 
5
Exhibit 99.1
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Table B
(in thousands, except per share data)
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026202520262025
Sales$254,560 $240,678 $501,781 $475,100 
Cost of sales109,780 114,823 220,213 230,838 
Gross profit144,780 125,855 281,568 244,262 
Operating expenses:
Selling, general and administrative111,642 109,596 219,829 223,449 
Research and development46,930 48,118 92,965 98,333 
Acquired in-process research and development expenses— — — 75,217 
Litigation and settlement expense— 19,951 — 19,951 
Total operating expenses158,572 177,665 312,794 416,950 
Operating loss
(13,792)(51,810)(31,226)(172,688)
Total other income (expense), net(6,866)(5,912)(9,309)(7,123)
Loss before income taxes
(20,658)(57,722)(40,535)(179,811)
Income tax expense (benefit)510 (5,322)1,026 3,145 
Net loss
$(21,168)$(52,400)$(41,561)$(182,956)
Net loss per share - basic and diluted
$(0.31)$(0.78)$(0.60)$(2.74)
Weighted average shares used to compute basic and diluted net loss per share
69,011 67,050 68,706 66,729 
6
Exhibit 99.1

TANDEM DIABETES CARE, INC.
SALES BY GEOGRAPHY AND NON-GAAP RECONCILIATION OF CONSTANT CURRENCY SALES GROWTH
Table C
(Unaudited)
($'s in thousands)Three Months Ended
June 30,
20262025% Change
Currency Impact
% Change Constant Currency
United States:
Pump$83,002 $85,467 (3)%
Supplies and other96,290 84,742 14%
Total Sales in the United States
$179,292 $170,209 5%—%5%
International:
Pump$31,650 $26,404 20%
Supplies and other43,618 44,065 (1)%
Total International Sales
$75,268 $70,469 7%1%6%
Total Worldwide Sales$254,560 $240,678 6%1%5%
($'s in thousands)Six Months Ended
June 30,
20262025% Change
Currency Impact
% Change Constant Currency
United States:
Pump$160,943 $157,608 2%
Supplies and other179,192 163,233 10%
Total Sales in the United States
$340,135 $320,841 6%—%6%
International:
Pump$64,135 $56,354 14%
Supplies and other97,511 97,905 —%
Total International Sales
$161,646 $154,259 5%5%—%
Total Worldwide Sales$501,781 $475,100 6%2%4%


7
Exhibit 99.1
TANDEM DIABETES CARE, INC.
RECONCILIATION OF GAAP VERSUS NON-GAAP FINANCIAL RESULTS
Table D
(Unaudited)
($'s in thousands)Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
GAAP operating loss
$(13,792)$(51,810)$(31,226)$(172,688)
Litigation and settlement expense—19,951—19,951
Non-recurring facility impairment and restructuring costs(1)
———11,167
Non-GAAP operating loss$(13,792)$(31,859)$(31,226)$(141,570)
GAAP operating margin(2)
(5)%(22)%(6)%(36)%
Non-GAAP operating margin(2)
(5)%(13)%(6)%(30)%
GAAP net loss
$(21,168)$(52,400)$(41,561)$(182,956)
Income tax expense (benefit)510(5,322)1,0263,145
Interest income, interest expense and other, net6,8665,9129,3097,123
Depreciation and amortization4,4704,3678,9748,678
Litigation and settlement expense—19,951—19,951
Stock-based compensation expense15,74025,64131,40051,130
Non-recurring facility impairment and restructuring costs(1)
———11,167
Adjusted EBITDA$6,418$(1,851)$9,148$(81,762)
Adjusted EBITDA margin(2)
3 %(1)%2 %(17)%
GAAP net loss
$(21,168)$(52,400)$(41,561)$(182,956)
Litigation and settlement expense—19,951—19,951
Non-recurring facility impairment and restructuring costs(1)
———11,167
Non-GAAP net loss$(21,168)$(32,449)$(41,561)$(151,838)
GAAP cash used in operating activities$(34,623)$(9,495)$(23,576)$(27,774)
Less: capital expenditures
(4,050)(6,207)(10,318)(9,171)
Non-GAAP free cash flow (3)
$(38,673)$(15,702)$(33,894)$(36,945)
(1) In the first quarter of 2025, the Company recorded $11.2 million in impairment charges related to its operating lease right-of-use assets, and severance and other restructuring costs associated with the relocation of certain research and development activities.
(2) GAAP margins, including GAAP gross margin and GAAP operating margin, and non-GAAP margins, including non-GAAP operating margin and adjusted EBITDA margin, are calculated using GAAP sales.
(3) Free cash flow is a non-GAAP financial measure that the Company defines as cash provided by operating activities less capital expenditures.
8

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents